Skip to main content
SpringerLink
Log in
Book cover

Cannabinoid Modulation of Emotion, Memory, and Motivation pp 363–391Cite as

Cannabinoid-Alcohol Interactions

  • Chapter
  • First Online:

Abstract

Marijuana and alcohol are two of the most commonly abused substances worldwide. Although the psychotropic effects of these drugs are mediated by distinct pharmacodynamic mechanisms, the similar physiological and neuropsychological effects of these drugs have long been recognized. This chapter focuses on interactive effects between cannabinoids and alcohol with a particular emphasis on the influence of endogenous cannabinoid (eCB) signaling on the motivation for alcohol consumption and the etiology of alcohol use disorders. Topics include the modulation of alcohol consumption by exogenous cannabinoid receptor agonists and antagonists, the influence of alcohol exposure on brain eCB formation and alcohol-induced disruptions in eCB-mediated synaptic plasticity. Associations between genetic variants in eCB signaling with alcohol use disorders are discussed along with a possible role of dysregulated eCB signaling in symptoms of alcohol dependence and protracted withdrawal. The chapter concludes with a brief consideration of the eCB system as a viable treatment target for alcohol dependence.

The original version of this chapter was revised. An erratum to this chapter can be found at DOI 10.1007/978-1-4939-2294-9_18

An erratum to this chapter can be found at http://dx.doi.org/10.1007/978-1-4939-2294-9_18

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. SAMHSA. Results from the 2012 National survey on drug use and health: summary of national findings. Rockville: Office of Applied Studies, DHHS; 2013.

    Google Scholar 

  2. White HR, Morgan TJ, Pugh LA, Celinska K, Labouvie EW, Pandina RJ. Evaluating two brief substance-use interventions for mandated college students. J Stud Alcohol. 2006;67(2):309–17.

    Article  PubMed  Google Scholar 

  3. Welfare AloHa. 2007 National Drug Strategy Household Survey: First results. Canberra: Australian Institute of Health and Welfare; 2008.

    Google Scholar 

  4. Hedden SL, Martins SS, Malcolm RJ, Floyd L, Cavanaugh CE, Latimer WW. Patterns of illegal drug use among an adult alcohol dependent population: results from the national survey on drug use and health. Drug Alcohol Depend. 2010;106(2–3):119–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Magill M, Barnett NP, Apodaca TR, Rohsenow DJ, Monti PM. The role of marijuana use in brief motivational intervention with young adult drinkers treated in an emergency department. J Stud Alcohol Drugs. 2009;70(3):409–13.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Peters EN, Leeman RF, Fucito LM, Toll BA, Corbin WR, O’Malley SS. Co-occurring marijuana use is associated with medication nonadherence and nonplanning impulsivity in young adult heavy drinkers. Addict Behav. 2012;37(4):420–6.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Jones RT, Stone GC. Psychological studies of marijuana and alcohol in man. Psychopharmacologia. 1970;18(1):108–17.

    Article  CAS  PubMed  Google Scholar 

  8. Macavoy MG, Marks DF. Divided attention performance of cannabis users and non-users following cannabis and alcohol. Psychopharmacologia. 1975;44(2):147–52.

    Article  CAS  PubMed  Google Scholar 

  9. Newman LM, Lutz MP, Gould MH, Domino EF. 9-Tetrahydrocannabinol and ethyl alcohol: evidence for cross-tolerance in the rat. Science. 1972;175(4025):1022–3.

    Article  CAS  PubMed  Google Scholar 

  10. Newman LM, Lutz MP, Domino EF. Delta9-tetrahydrocannabinol and some CNS depressants: evidence for cross-tolerance in the rat. Arch Int Pharmacodyn Ther. 1974;207(2):254–9.

    CAS  PubMed  Google Scholar 

  11. Sprague GL, Craigmill AL. Ethanol and delta-9-tetrahydrocannabinol: mechanism for cross-tolerance in mice. Pharmacol Biochem Behav. 1976;5(4):409–15.

    Article  CAS  PubMed  Google Scholar 

  12. Siemens AJ, Doyle OL. Cross-tolerance between delta9-tetrahydrocannabinol and ethanol: the role of drug disposition. Pharmacol Biochem Behav. 1979;10(1):49–55.

    Article  CAS  PubMed  Google Scholar 

  13. McMillan DE, Snodgrass SH. Effects of acute and chronic administration of delta9-tetrahy-drocannabinol or cocaine on ethanol intake in a rat model. Drug Alcohol Depend. 1991;27(3):263–74.

    Article  CAS  PubMed  Google Scholar 

  14. da Silva GE, Morato GS, Takahashi RN. Rapid tolerance to Delta(9)-tetrahydrocannabinol and cross-tolerance between ethanol and Delta(9)-tetrahydrocannabinol in mice. Eur J Pharmacol. 2001;431(2):201–7.

    Article  PubMed  Google Scholar 

  15. Lemos JI, Takahashi RN, Morato GS. Effects of SR141716 and WIN 55,212-2 on tolerance to ethanol in rats using the acute and rapid procedures. Psychopharmacology (Berl). 2007;194(2):139–49.

    Article  CAS  Google Scholar 

  16. Pava MJ, Blake EM, Green ST, Mizroch BJ, Mulholland PJ, Woodward JJ. Tolerance to cannabinoid-induced behaviors in mice treated chronically with ethanol. Psychopharmacology (Berl). 2012;219(1):137–47.

    Article  CAS  Google Scholar 

  17. Hollister LE, Gillespie HK. Marihuana, ethanol, and dextroamphetamine. Mood and mental function alterations. Arch Gen Psychiatry. 1970;23(3):199–203.

    Article  CAS  PubMed  Google Scholar 

  18. Kalant H, LeBlanc AE. Effect of acute and chronic pre-treatment with delta1-tetrahydrocannabinol on motor impairment by ethanol in the rat. Can J Physiol Pharmacol. 1974;52(2):291–7.

    Article  CAS  PubMed  Google Scholar 

  19. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, Ward SJ. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav. 1991;40(3):471–8.

    Article  CAS  PubMed  Google Scholar 

  20. Crabbe JC, Metten P, Cameron AJ, Wahlsten D. An analysis of the genetics of alcohol intoxication in inbred mice. Neurosci Biobehav Rev. 2005;28(8):785–802.

    Article  CAS  PubMed  Google Scholar 

  21. Heishman SJ, Stitzer ML, Bigelow GE. Alcohol and marijuana: comparative dose effect profiles in humans. Pharmacol Biochem Behav. 1988;31(3):649–55.

    Article  CAS  PubMed  Google Scholar 

  22. Chait LD, Perry JL. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. Psychopharmacology (Berl). 1994;115(3):340–9.

    Article  CAS  Google Scholar 

  23. Heishman SJ, Arasteh K, Stitzer ML. Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav. 1997;58(1):93–101.

    Article  CAS  PubMed  Google Scholar 

  24. Manno JE, Kiplinger GF, Scholz N, Forney RB. The influence of alcohol and marihuana on motor and mental performance. Clin Pharmacol Ther. 1971;12(2):202–11.

    Article  CAS  PubMed  Google Scholar 

  25. Marks DF, MacAvoy MG. Divided attention performance in cannabis users and non-users following alcohol and cannabis separately and in combination. Psychopharmacology (Berl). 1989;99(3):397–401.

    Article  CAS  Google Scholar 

  26. Phillips RN, Brown DJ, Forney RB. Enhancement of depressant properties of alcohol or barbiturate in combination with aqueous suspended delta9-tetrahydrocannabinol in rats. J Forensic Sci. 1971;16(2):152–61.

    CAS  PubMed  Google Scholar 

  27. Zarcone VP, Jr. Marijuana and ethanol: effects on sleep. Int J Psychiatry Med. 1973;4(2):201–12.

    Article  PubMed  Google Scholar 

  28. Friedman E, Gershon S. Effect of delta8-THC on alcohol-induced sleeping time in the rat. Psychopharmacologia. 1974;39(3):193–8.

    Article  CAS  PubMed  Google Scholar 

  29. Bech P, Rafaelsen L, Rafaelsen OJ. Cannabis and alcohol: effects on estimation of time and distance. Psychopharmacologia. 1973;32(4):373–81.

    Article  CAS  PubMed  Google Scholar 

  30. Tinklenberg JR, Roth WT, Kopell BS. Marijuana and ethanol: differential effects on time perception, heart rate, and subjective response. Psychopharmacology (Berl). 1976;49(3):275–9.

    Article  CAS  Google Scholar 

  31. Colombo G, Serra S, Brunetti G, Gomez R, Melis S, Vacca G, Carai MAM, Gessa GL. Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats. Psychopharmacology (Berl). 2002;159(2):181–7.

    Article  CAS  Google Scholar 

  32. Kelai S, Hanoun N, Aufrere G, Beauge F, Hamon M, Lanfumey L. Cannabinoid-serotonin interactions in alcohol-preferring vs. alcohol-avoiding mice. J Neurochem. 2006;99(1):308–20.

    Article  CAS  PubMed  Google Scholar 

  33. Vinod KY, Yalamanchili R, Thanos PK, Vadasz C, Cooper TB, Volkow ND, Hungund BL. Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice. Synapse. 2008;62(8):574–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Linsenbardt DN, Boehm SL. 2nd. Agonism of the endocannabinoid system modulates binge-like alcohol intake in male C57BL/6J mice: involvement of the posterior ventral tegmental area. Neuroscience. 2009;164(2):424–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Malinen H, Hyytiä P. Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. Alcohol Clin Exp Res. 2008;32(11):1976–83.

    CAS  PubMed  Google Scholar 

  36. Getachew B, Hauser SR, Dhaher R, Katner SN, Bell RL, Oster SM, McBride WJ, Rodd ZA. CB1 receptors regulate alcohol-seeking behavior and alcohol self-administration of alcohol-preferring (P) rats. Pharmacol Biochem Behav. 2011;97(4):669–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Gallate JE, Saharov T, Mallet PE, McGregor IS. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur J Pharmacol. 1999;370(3):233–40.

    Article  CAS  PubMed  Google Scholar 

  38. Spanagel R. How to measure relapse in animals. In: Spanagel R, Mann KF, editors. Drugs for relapse prevention of alcoholism. Basel: Birkhäuser; 2005. p. 13–21.

    Chapter  Google Scholar 

  39. Martin-Fardon R, Weiss F. Modeling relapse in animals. Curr Top Behav Neurosci. 2013;13:403–32.

    Article  PubMed  Google Scholar 

  40. Lopez-Moreno JA, Gonzalez-Cuevas G, Rodríguez de Fonseca F, Navarro M. Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation. J Neurosci. 2004;24(38):8245–52.

    Article  CAS  PubMed  Google Scholar 

  41. Alén F, Moreno-Sanz G, Isabel de Tena A, Brooks RD, López-Jimenez A, Navarro M, López-Moreno JA. Pharmacological activation of CB1 and D2 receptors in rats: predominant role of CB1 in the increase of alcohol relapse. Eur J Neurosci. 2008;27(12):3292–8.

    Article  PubMed  Google Scholar 

  42. Alén F, Santos A, Moreno-Sanz G, González-Cuevas G, Giné E, Franco-Ruiz L, Navarro M, López-Moreno JA. Cannabinoid-induced increase in relapse-like drinking is prevented by the blockade of the glycine-binding site of N-methyl-D-aspartate receptors. Neuroscience. 2009;158(2):465–73.

    Article  PubMed  CAS  Google Scholar 

  43. McGregor IS, Dam KD, Mallet PE, Gallate JE. Delta9-THC reinstates beer- and sucrose-seeking behaviour in abstinent rats: comparison with midazolam, food deprivation and predator odour. Alcohol Alcohol. 2005;40(1):35–45.

    Article  CAS  PubMed  Google Scholar 

  44. Colombo G, Serra S, Vacca G, Gessa GL, Carai MAM. Suppression by baclofen of the stimulation of alcohol intake induced by morphine and WIN 55,212-2 in alcohol-preferring rats. Eur J Pharmacol. 2004;492(2–3):189–93.

    Article  CAS  PubMed  Google Scholar 

  45. Colombo G, Orrù A, Lai P, Cabras C, Maccioni P, Rubio M, Gessa GL, Carai MAM. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol. 2007;36(1):102–12.

    Article  CAS  PubMed  Google Scholar 

  46. Mechoulam R, Parker L. Cannabis and alcohol-a close friendship. Trends Pharmacol Sci. 2003;24(6):266–8.

    Article  CAS  PubMed  Google Scholar 

  47. Gessa GL, Muntoni F, Collu M, Vargiu L, Mereu G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res. 1985;348(1):201–3.

    Article  CAS  PubMed  Google Scholar 

  48. Imperato A, Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther. 1986;239(1):219–28.

    CAS  PubMed  Google Scholar 

  49. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997;276(5321):2048–50.

    Article  CAS  PubMed  Google Scholar 

  50. Gessa GL, Melis M, Muntoni AL, Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol. 1998;341(1):39–44.

    Article  CAS  PubMed  Google Scholar 

  51. Arnone M, Maruani J, Chaperon F, Thiébot MH, Poncelet M, Soubrié P, Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl). 1997;132(1):104–6.

    Article  CAS  Google Scholar 

  52. Colombo G, Agabio R, Fà M, Guano L, Lobina C, Loche A, Reali R, Gessa GL. Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcohol. 1998;33(2):126–30.

    Article  CAS  PubMed  Google Scholar 

  53. Serra S, Carai MAM, Brunetti G, Gomez R, Melis S, Vacca G, Colombo G, Gessa GL. The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats. Eur J Pharmacol. 2001;430(2–3):369–71.

    Article  CAS  PubMed  Google Scholar 

  54. Vinod KY, Maccioni P, Garcia-Gutierrez MS, Femenia T, Xie S, Carai MAM, Manzanares J, Cooper TB, Hungund BL, Colombo G. Innate difference in the endocannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats. Addict Biol. 2012;17(1):62–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Bell RL, Rodd ZA, Sable HJK, McQueen VK, Davids MR, Murphy JM, Lumeng L, McBride WJ. Cannabinoid CB1 antagonist reduces alcohol intake during acquisition, maintenance, and relapse in inbred alcohol preferring (IP) rats. Soc Neurosci. 2004. Program No. 489.6.

    Google Scholar 

  56. Lallemand F, Soubrie PH, De Witte PH. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcohol Clin Exp Res. 2001;25(9):1317–23.

    Article  CAS  PubMed  Google Scholar 

  57. Poncelet M, Maruani J, Calassi R, Soubrie P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett. 2003;343(3):216–8.

    Article  CAS  PubMed  Google Scholar 

  58. Hungund BL, Szakall I, Adam A, Basavarajappa BS, Vadasz C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem. 2003;84(4):698–704.

    Article  CAS  PubMed  Google Scholar 

  59. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci USA. 2003;100(3):1393–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Naassila M, Pierrefiche O, Ledent C, Daoust M. Decreased alcohol self-administration and increased alcohol sensitivity and withdrawal in CB1 receptor knockout mice. Neuropharmacology. 2004;46(2):243–53.

    Article  CAS  PubMed  Google Scholar 

  61. Lallemand F, de Witte P. Ethanol induces higher BEC in CB1 cannabinoid receptor knockout mice while decreasing ethanol preference. Alcohol Alcohol. 2005;40(1):54–62.

    Article  CAS  PubMed  Google Scholar 

  62. Racz I, Bilkei-Gorzo A, Toth ZE, Michel K, Palkovits M, Zimmer A. A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci. 2003;23(6):2453–8.

    CAS  PubMed  Google Scholar 

  63. Dyr W, Ligieza J, Kostowski W. The effect of cannabinoid CB(1) receptor antagonist rimonabant (SR-141716) on ethanol drinking in high-preferring rats. Alcohol. 2008;42(6):509–12.

    Article  CAS  PubMed  Google Scholar 

  64. Gallate JE, Mallet PE, McGregor IS. Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats. Psychopharmacology (Berl). 2004;173(1–2):210–6.

    Article  CAS  Google Scholar 

  65. Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res. 2005;164(2):206–13.

    Article  CAS  PubMed  Google Scholar 

  66. Hansson AC, Bermúdez-Silva FJ, Malinen H, Hyytiä P, Sanchez-Vera I, Rimondini R, Rodríguez de Fonseca F, Kunos G, Sommer WH, Heilig M. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology. 2007;32(1):117–26.

    Article  CAS  PubMed  Google Scholar 

  67. Maccioni P, Fantini N, Carai MAM, Gessa GL, Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, rimonabant, on alcohol self-administration in alcohol-preferring rats. Open Neuropsychopharmacol. 2009;2:40–4.

    Article  CAS  Google Scholar 

  68. Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V, Trabace L, Ciccocioppo R. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl). 2006;183(4):394–403.

    Article  CAS  Google Scholar 

  69. Pavon FJ, Bilbao A, Hernández-Folgado L, Cippitelli A, Jagerovic N, Abellán G, Rodríguez-Franco MA, Serrano A, Macias M, Gómez R, Navarro M, Goya P, Rodríguez de Fonseca F. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH21. Neuropharmacology. 2006;51(2):358–66.

    Article  CAS  PubMed  Google Scholar 

  70. Cippitelli A, Cannella N, Braconi S, Duranti A, Tontini A, Bilbao A, Rodríguez de Fonseca F, Piomelli D, Ciccocioppo R. Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Psychopharmacology (Berl). 2008;198(4):449–60.

    Article  CAS  Google Scholar 

  71. Colombo G, Vacca G, Serra S, Carai MAM, Gessa GL. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol’s motivational properties in alcohol-preferring rats. Eur J Pharmacol. 2004;498(1–3):119–23.

    Article  CAS  PubMed  Google Scholar 

  72. Maccioni P, Pes D, Carai MAM, Gessa GL, Colombo G. Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats. Behav Pharmacol. 2008;19(3):197–209.

    Article  CAS  PubMed  Google Scholar 

  73. Caille S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci. 2007;27(14):3695–702.

    Article  CAS  PubMed  Google Scholar 

  74. Alvarez-Jaimes L, Polis I, Parsons LH. Regional influence of cannabinoid CB1 receptors in the regulation of ethanol self-administration by Wistar rats. Open Neuropsychopharmacol. 2009;2:77–85.

    Article  CAS  Google Scholar 

  75. Koob GF, Le Moal M. Neurobiology of Addiction. London:Elsevier; 2006.

    Google Scholar 

  76. Serra S, Brunetti G, Pani M, Vacca G, Carai MAM, Gessa GL, Colombo G. Blockade by the cannabinoid CB(1) receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats. Eur J Pharmacol. 2002;443(1–3):95–7.

    Article  CAS  PubMed  Google Scholar 

  77. Shaham Y, Erb S, Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Rev. 2000;33(1):13–33.

    Article  CAS  PubMed  Google Scholar 

  78. Stewart J. Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking. J Psychiatr Neurosci. 2000;25(2):125–36.

    CAS  Google Scholar 

  79. See RE. Neural substrates of cocaine-cue associations that trigger relapse. Eur J Pharmacol. 2005;526(1–3):140–6.

    Article  CAS  PubMed  Google Scholar 

  80. Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr Opin Pharmacol. 2005;5(1):9–19.

    Article  CAS  PubMed  Google Scholar 

  81. Ren K, Bristow LJ, Fong T, Lorrain DS, Morse AC. The cannabinoid CB1 inverse agonist AM251 attenuates alcohol self-administration and the alcohol deprivation effect. Soc Neurosci. 2004. Program No. 117.11.

    Google Scholar 

  82. Gessa GL, Serra S, Vacca G, Carai MAM, Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol. 2005;40(1):46–53.

    Article  CAS  PubMed  Google Scholar 

  83. Lallemand F, De Witte P. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. Alcohol. 2006;39(3):125–34.

    Article  CAS  PubMed  Google Scholar 

  84. Femenia T, Garcia-Gutierrez MS, Manzanares J. CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats. Alcohol Clin Exp Res. 2010;34(1):131–41.

    Article  CAS  PubMed  Google Scholar 

  85. de Bruin NM, Lange JH, Kruse CG, Herremans AH, Schoffelmeer AN, van Drimmelen M, De Vries TJ. SLV330, a cannabinoid CB(1) receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats. Behav Brain Res. 2011;217(2):408–15.

    Article  PubMed  CAS  Google Scholar 

  86. Dean RL, Eyerman D, Todtenkopf MS, Turncliff RZ, Bidlack JM, Deaver DR. Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats. Pharmacol Biochem Behav. 2012;100(3):530–7.

    Article  CAS  PubMed  Google Scholar 

  87. Carai MAM, Lobina C, Gessa GL, Colombo G. Cannabinoid receptor antagonists: a perspective. In: Spanagel R, Mann KF, editors. Drugs for relapse prevention of alcoholism. Basel: Birkhauser; 2005. pp. 181–7.

    Chapter  Google Scholar 

  88. Colombo G, Serra S, Vacca G, Carai MAM, Gessa GL. Effect of the combination of naltrexone and baclofen, on acquisition of alcohol drinking behavior in alcohol-preferring rats. Drug Alcohol Depend. 2005;77(1):87–91.

    Article  CAS  PubMed  Google Scholar 

  89. Manzanares J, Ortiz S, Oliva JM, Perez-Rial S, Palomo T. Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects. Alcohol Alcohol. 2005;40(1):25–34.

    Article  CAS  PubMed  Google Scholar 

  90. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946–9.

    Article  CAS  PubMed  Google Scholar 

  91. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, GopherA, Almog S, Martin BR, Compton DR. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50(1):83–90.

    Google Scholar 

  92. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A. WakuK. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215(1):89–97.

    Article  CAS  PubMed  Google Scholar 

  93. Bisogno T, Melck D, Bobrov M, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J. 2000;351(3):817–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem. 1993;36(20):3032–4.

    Article  CAS  PubMed  Google Scholar 

  95. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I. Mechoulam R. 2-arachidonyl glyceryl ether. an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA. 2001;98(7):3662–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Pertwee R, Griffin G, Hanus L, Mechoulam R. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur J Pharmacol. 1994;259(2):115–20.

    Article  CAS  PubMed  Google Scholar 

  97. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther. 2002;301(3):1020–4.

    Article  CAS  PubMed  Google Scholar 

  98. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J. 2007;173(1):21–30.

    Article  CAS  PubMed  Google Scholar 

  99. Rodríguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J, Murillo -RodríguezE, Giuffrida A, LoVerme J, Gaetani S, Kathuria S, Gall C, Piomelli D. An anorexic lipid mediator regulated by feeding. Nature. 2001;414(6860):209–12.

    Article  PubMed  Google Scholar 

  100. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci. 1996;16(12):3934–42.

    CAS  PubMed  Google Scholar 

  101. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4(11):873–84.

    Article  CAS  PubMed  Google Scholar 

  102. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem. 2004;279(7):5298–305.

    Article  CAS  PubMed  Google Scholar 

  103. Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, Palmiter RD, Krystal G, Rai R, Mahadevan A, Razdan RK, Kunos G. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology. 2008;54(1):1–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem. 2006;281(36):26465–72.

    Google Scholar 

  105. Simon GM, Cravatt BF. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem. 2008;283(14):9341–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388(6644):773–8.

    Article  CAS  PubMed  Google Scholar 

  107. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997;277(5329):1094–7.

    Article  CAS  PubMed  Google Scholar 

  108. Hillard CJ, Jarrahian A. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids. 2000;108(1–2):123–34.

    Article  CAS  PubMed  Google Scholar 

  109. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Ann Rev Biochem. 2005;74:411–32.

    Article  CAS  PubMed  Google Scholar 

  110. Fezza F, De Simone C, Amadio D, Maccarrone M. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell Biochem. 2008;49:101–32.

    Article  PubMed  Google Scholar 

  111. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol. 2007;14(12):1347–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, Bodor AL, Muccioli GG, Hu SS, Woodruff G, Fung S, Lafourcade M, Alexander JP, Long JZ, Li W, Xu C, Möller T, Mackie K, Manzoni OJ, Cravatt BF, Stella N. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci. 2010;13(8):951–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, Freund TF. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci. 2004;20(2):441–58.

    Article  CAS  PubMed  Google Scholar 

  114. Ludanyi A, Hu SS, Yamazaki M, Tanimura A, Piomelli D, Watanabe M, Kano M, Sakimura K, Maglóczky Z, Mackie K, Freund TF, Katona I. Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience. 2011;174:50–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Straiker A, Hu SS, Long JZ, Arnold A, Wager-Miller J, Cravatt BF, Mackie K. Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. Mol Pharmacol. 2009;76(6):1220–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Kim J, Alger BE. Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. Nat Neurosci. 2010;13(5):592–600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbaschek R, Garcia N Jr, Sanyal AJ, Kunos G. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med. 2001;7(7):827–32.

    Article  CAS  PubMed  Google Scholar 

  118. Herkenham M. Characterization and localization of cannabinoid receptors in brain: an in vitro technique using slide-mounted tissue sections. NIDA Res Monogr. 1991;112:129–45.

    CAS  PubMed  Google Scholar 

  119. Herkenham M, Groen BG, Lynn AB, De Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Res. 1991;552(2):301–10.

    Article  CAS  PubMed  Google Scholar 

  120. Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 1991;547(2):267–74.

    Article  CAS  PubMed  Google Scholar 

  121. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11(2):563–83.

    CAS  PubMed  Google Scholar 

  122. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87(5):1932–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 1990;13(10):420–3.

    Article  CAS  PubMed  Google Scholar 

  124. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232(1):54–61.

    Article  PubMed  Google Scholar 

  125. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5.

    Article  CAS  PubMed  Google Scholar 

  126. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F. CB2 receptors in the brain: role in central immune function. Br J Pharmacol. 2008;153(2):240–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng XD, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007;13(4):492–7.

    Article  CAS  PubMed  Google Scholar 

  128. Stella N. Cannabinoid signaling in glial cells. Glia. 2004;48(4):267–77.

    Article  PubMed  Google Scholar 

  129. Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol. 2007;5(2):73–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, Perchuk A, MoraZ, Tagliaferro PA, Gardner E, Brusco A, Akinshola BE, Hope B, Lujilde J, Inada T, Iwasaki S, Macharia D, Teasenfitz L, Arinami T, Uhl GR. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PloS One. 2008;3(2):e1640.

    Google Scholar 

  131. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L, MoraZ, Tagliaferro P, Gardner E, Brusco A, Akinshola BE, Liu QR, Hope B, Iwasaki S, Arinami T, Teasenfitz L, Uhl GR. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann New York Acad Sci. 2006;1074:514–36.

    Google Scholar 

  132. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, StellaN, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310(5746):329–32.

    Google Scholar 

  133. Aracil-Fernandez A, Trigo JM, Garcia-Gutierrez MS, Ortega-Alvaro A, Ternianov A, Navarro D, Robledo P, Berbel P, Maldonado R, Manzanares J. Decreased cocaine motor sensitization and self-administration in mice overexpressing cannabinoid CB(2) receptors. Neuropsychopharmacology. 2012;37(7):1749–63.

    Google Scholar 

  134. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA. 1992;89(9):3825–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci. 1995;15(10):6552–61.

    CAS  PubMed  Google Scholar 

  136. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol. 1997;78(1):43–50.

    CAS  PubMed  Google Scholar 

  137. Pertwee RG. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem. 2010;17(14):1360–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA. 2008;105(7):2699–704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006;3(3):167–75.

    Article  CAS  PubMed  Google Scholar 

  140. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, ElebringT, Nilsson K, Drmota T, Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152(7):1092–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Sharir H, Abood ME. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther. 2010;126(3):301–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, JuliusD, Högestätt ED. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400(6743):452–7.

    Article  CAS  PubMed  Google Scholar 

  143. Basavarajappa BS, Cooper TB, Hungund BL. Chronic ethanol administration down-regulates cannabinoid receptors in mouse brain synaptic plasma membrane. Brain Res. 1998;793(1–2):212–8.

    Article  CAS  PubMed  Google Scholar 

  144. Basavarajappa BS, Hungund BL. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells. J Neurochem. 1999;72(2):522–8.

    Article  CAS  PubMed  Google Scholar 

  145. Vinod KY, Yalamanchili R, Xie S, Cooper TB, Hungund BL. Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system. Neurochem Int. 2006;49(6):619–25.

    Article  CAS  PubMed  Google Scholar 

  146. Moranta D, Esteban S, Garcia-Sevilla JA. Ethanol desensitizes cannabinoid CB1 receptors modulating monoamine synthesis in the rat brain in vivo. Neurosci Lett. 2006;392(1–2):58–61.

    Article  CAS  PubMed  Google Scholar 

  147. Mitrirattanakul S, Lopez-Valdes HE, Liang J, Matsuka Y, Mackie K, Faull KF, Spigelman I. Bidirectional alterations of hippocampal cannabinoid 1 receptors and their endogenous ligands in a rat model of alcohol withdrawal and dependence. Alcohol Clin Exp Res. 2007;31(5):855–67.

    Article  CAS  PubMed  Google Scholar 

  148. Ceccarini J, Casteels C, Koole M, Bormans G, Van Laere K. Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study. Eur J Nucl Med Mol Imaging. 2013;40(10):1582–94.

    Article  CAS  PubMed  Google Scholar 

  149. Vinod KY, Arango V, Xie S, Kassir SA, Mann JJ, Cooper TB, Hungund BL. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry. 2005;57(5):480–6.

    Article  CAS  PubMed  Google Scholar 

  150. Vinod KY, Kassir SA, Hungund BL, Cooper TB, Mann JJ, Arango V. Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides. J Psychiatr Res. 2010;44(9):591–7.

    Article  PubMed  PubMed Central  Google Scholar 

  151. Hirvonen J, Zanotti-Fregonara P, Umhau JC, George DT, Rallis-Frutos D, Lyoo CH, Li CT, Hines CS, Sun H, Terry GE, Morse C, Zoghbi SS, Pike VW, Innis RB, Heilig M. Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry. 2013;18(8):916–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Ceccarini J, Hompes T, Verhaeghen A, Casteels C, Peuskens H, Bormans G, Claes S, Van Laere K. Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence. J Neurosci. 2014;34(8):2822–31.

    Article  CAS  PubMed  Google Scholar 

  153. Neumeister A, Normandin MD, Murrough JW, Henry S, Bailey CR, Luckenbaugh DA, Tuit K, Zheng MQ, Galatzer-Levy IR, Sinha R, Carson RE, Potenza MN, Huang Y. Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence. Alcohol Clin Exp Res. 2012;36(12):2104–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Agudelo M, Yndart A, Morrison M, Figueroa G, Munoz K, Samikkannu T, Nair MP. Differential expression and functional role of cannabinoid genes in alcohol users. Drug Alcohol Depend. 2013;133(2):789–93.

    Article  CAS  PubMed  Google Scholar 

  155. Oviedo A, Glowa J, Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 1993;616(1–2):293–302.

    Article  CAS  PubMed  Google Scholar 

  156. Romero J, Berrendero F, Garcia-Gil L, Ramos JA, Fernandez-Ruiz JJ. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta9-tetrahydrocannabinol. J Mol Neurosci. 1998;11(2):109–19.

    Article  CAS  PubMed  Google Scholar 

  157. Romero J, Garcia L, Fernandez-Ruiz JJ, Cebeira M, Ramos JA. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta9-tetrahydrocannabinol. Pharmacol Biochem Behav. 1995;51(4):731–7.

    Article  CAS  PubMed  Google Scholar 

  158. Serrano A, Rivera P, Pavon FJ, Decara J, Suarez J, Rodríguez de Fonseca F, Parsons LH. Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system-related genes in the rat amygdala. Alcohol Clin Exp Res. 2012;36(6):984–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Basavarajappa BS, Saito M, Cooper TB, Hungund BL. Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons. Biochim Biophys Acta. 2000;1535(1):78–86.

    Article  CAS  PubMed  Google Scholar 

  160. Basavarajappa BS, Saito M, Cooper TB, Hungund BL. Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons. Eur J Pharmacol. 2003;466(1–2):73–83.

    Article  CAS  PubMed  Google Scholar 

  161. Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 2002;954(1):73–81.

    Article  CAS  PubMed  Google Scholar 

  162. Gonzalez S, Valenti M, de Miguel R, Fezza F, Fernandez-Ruiz J, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. Br J Pharmacol. 2004;143(4):455–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. Malinen H, Lehtonen M, Hyytiä P. Modulation of brain endocannabinoid levels by voluntary alcohol consumption in alcohol-preferring AA rats. Alcohol Clin Exp Res. 2009;33(10):1711–20.

    Article  CAS  PubMed  Google Scholar 

  164. Rubio M, McHugh D, Fernandez-Ruiz J, Bradshaw H, Walker JM. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. Neurosci Lett. 2007;421(3):270–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Buczynski MW, Parsons LH. Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br J Pharmacol. 2010;160(3):423–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. Ferrer B, Bermudez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, Giuffrida A, Serrano A, Baixeras E, Khaturia S, Navarro M, Parsons LH, Piomelli D, Rodríguez de Fonseca F. Regulation of brain anandamide by acute administration of ethanol. Biochem J. 2007;404(1):97–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  167. Alvarez-Jaimes L, Stouffer DG, Parsons LH. Chronic ethanol treatment potentiates ethanol-induced increases in interstitial nucleus accumbens endocannabinoid levels in rats. J Neurochem. 2009;111(1):37–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 2001;29(3):717–27.

    Article  CAS  PubMed  Google Scholar 

  169. Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron. 2001;31(3):463–75.

    Article  CAS  PubMed  Google Scholar 

  170. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 2001;29(3):729–38.

    Article  CAS  PubMed  Google Scholar 

  171. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678–82.

    Article  CAS  PubMed  Google Scholar 

  172. Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol. 2002;68(4):247–86.

    Article  CAS  PubMed  Google Scholar 

  173. Diana MA, Marty A. Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol. 2004;142(1):9–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Chevaleyre V, Takahashi KA, Castillo PE. Endocannabinoid-mediated synaptic plasticity in the CNS. Ann Rev Neurosci. 2006;29:37–76.

    Article  CAS  PubMed  Google Scholar 

  175. Marsicano G, Lutz B. Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest. 2006;29(3 Suppl):27–46.

    CAS  PubMed  Google Scholar 

  176. Lovinger DM. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol. 2008;184:435–77.

    Article  Google Scholar 

  177. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89(1):309–80.

    Article  CAS  PubMed  Google Scholar 

  178. Everitt BJ, Dickinson A, Robbins TW. The neuropsychological basis of addictive behaviour. Brain Res Rev. 2001;36(2–3):129–38.

    Article  CAS  PubMed  Google Scholar 

  179. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Ann Rev Neurosci. 2006;29:565–98.

    Article  CAS  PubMed  Google Scholar 

  180. Kauer JA, Malenka RC. Synaptic plasticity and addiction. Nat Rev Neurosci. 2007;8(11):844–58.

    Article  CAS  PubMed  Google Scholar 

  181. Kalivas PW, O’Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology. 2008;33(1):166–80.

    Article  CAS  PubMed  Google Scholar 

  182. Torregrossa MM, Corlett PR, Taylor JR. Aberrant learning and memory in addiction. Neurobiol Learn Mem. 2011;96(4):609–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  183. Adermark L, Lovinger DM. Frequency-dependent inversion of net striatal output by endocannabinoid-dependent plasticity at different synaptic inputs. J Neurosci. 2009 Feb 4;29(5):1375–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. Clarke RB, Adermark L. Acute ethanol treatment prevents endocannabinoid-mediated long-lasting disinhibition of striatal output. Neuropharmacology. 2010;58(4–5):799–805.

    Article  CAS  PubMed  Google Scholar 

  185. Adermark L, Jonsson S, Ericson M, Söderpalm B. Intermittent ethanol consumption depresses endocannabinoid-signaling in the dorsolateral striatum of rat. Neuropharmacology. 2011;61(7):1160–5.

    Article  CAS  PubMed  Google Scholar 

  186. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol. 2007;64(11):1575–9.

    Article  PubMed  Google Scholar 

  187. Yin HH, Ostlund SB, Balleine BW. Reward-guided learning beyond dopamine in the nucleus accumbens: the integrative functions of cortico-basal ganglia networks. Eur J Neurosci. 2008;28(8):1437–48.

    Article  PubMed  PubMed Central  Google Scholar 

  188. DePoy L, Daut R, Brigman JL, MacPherson K, Crowley N, Gunduz-Cinar O, Pickens CL, Cinar R, Saksida LM, Kunos G, Lovinger DM, Bussey TJ, Camp MC, Holmes A. Chronic alcohol produces neuroadaptations to prime dorsal striatal learning. Proc Natl Acad Sci USA. 2013;110(36):14783–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  189. Basavarajappa BS, Yalamanchili R, Cravatt BF, Cooper TB, Hungund BL. Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice. Neuropharmacology. 2006;50(7):834–44.

    Article  CAS  PubMed  Google Scholar 

  190. Blednov YA, Cravatt BF, Boehm SL, 2nd, Walker D, Harris RA. Role of endocannabinoids in alcohol consumption and intoxication: studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology. 2007;32(7):1570–82.

    Google Scholar 

  191. Vinod KY, Sanguino E, Yalamanchili R, Manzanares J, Hungund BL. Manipulation of fatty acid amide hydrolase functional activity alters sensitivity and dependence to ethanol. J Neurochem. 2008;104(1):233–43.

    CAS  PubMed  Google Scholar 

  192. Cippitelli A, Bilbao A, Gorriti MA, Navarro M, Massi M, Piomelli D, Ciccocioppo R, Rodríguez de Fonseca F. The anandamide transport inhibitor AM404 reduces ethanol self-administration. Eur J Neurosci. 2007;26(2):476–86.

    Article  PubMed  Google Scholar 

  193. Niphakis MJ, Cognetta AB 3rd, Chang JW, Buczynski MW, Parsons LH, Byrne F, Burston JJ, Chapman V, Cravatt BF. Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. ACS Chem Neurosci. 2013;4(9):1322–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  194. Chang JW, Niphakis MJ, Lum KM, Cognetta AB 3rd, Wang C, Matthews ML, NiessenS, Buczynski MW, Parsons LH, Cravatt BF. Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Chem Biol. 2012;19(5):579–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  195. Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, Massi M, Bermúdez-Silva FJ, Navarro M, Ciccocioppo R, Rodríguez de Fonseca F. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci. 2005;21(8):2243–51.

    Article  PubMed  Google Scholar 

  196. Dawson E, Gill M, Curtis D, Castle D, Hunt N, Murray R, Powell J. Genetic association between alleles of pancreatic phospholipase A2 gene and bipolar affective disorder. Psychiatr Genet. 1995;5(4):177–80.

    Article  CAS  PubMed  Google Scholar 

  197. Johnson JP, Muhleman D, MacMurray J, Gade R, Verde R, Ask M, Kelley J, ComingsDE. Association between the cannabinoid receptor gene (CNR1) and the P300 event-related potential. Mol Psychiatry. 1997;2(2):169–71.

    Article  CAS  PubMed  Google Scholar 

  198. Ehlers CL, Slutske WS, Lind PA, Wilhelmsen KC. Association between single nucleotide polymorphisms in the cannabinoid receptor gene (CNR1) and impulsivity in southwest California Indians. Twin Res Hum Genet. 2007;10(6):805–11.

    Article  PubMed  Google Scholar 

  199. Ponce G, Hoenicka J, Rubio G, Ampuero I, Jiménez-Arriero MA, Rodríguez-JiménezR, Palomo T, Ramos JA. Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients. Mol Psychiatry. 2003;8(5):466–7.

    Article  CAS  PubMed  Google Scholar 

  200. Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G, MacMurray J. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry. 1997;2(2):161–8.

    Article  CAS  PubMed  Google Scholar 

  201. Ballon N, Leroy S, Roy C, Bourdel MC, Charles-Nicolas A, Krebs MO, Poirier MF. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J. 2006;6(2):126–30.

    Article  CAS  PubMed  Google Scholar 

  202. Li T, Liu X, Zhu ZH, Zhao J, Hu X, Ball DM, Sham PC, Collier DA. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry. 2000;5(2):128–30.

    Article  PubMed  Google Scholar 

  203. Covault J, Gelernter J, Kranzler H. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Mol Psychiatry. 2001;6(5):501–2.

    Article  CAS  PubMed  Google Scholar 

  204. Heller D, Schneider U, Seifert J, Cimander KF, Stuhrmann M. The cannabinoid receptor gene (CNR1) is not affected in German i.v. drug users. Addict Biol. 2001;6(2):183–7.

    Article  CAS  PubMed  Google Scholar 

  205. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D, Onaivi ES, Arinami T, Uhl GR. Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry. 2004;9(10):916–31.

    Article  CAS  PubMed  Google Scholar 

  206. Hoehe MR, Caenazzo L, Martinez MM, Hsieh WT, Modi WS, Gershon ES, Bonner TI. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol. 1991;3(9):880–5.

    CAS  PubMed  Google Scholar 

  207. Gadzicki D, Muller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes. 1999;13(4):321–3.

    Article  CAS  PubMed  Google Scholar 

  208. Schmidt LG, Samochowiec J, Finckh U, Fiszer-Piosik E, Horodnicki J, Wendel B, Rommelspacher H, Hoehe MR. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend. 2002;65(3):221–4.

    Article  CAS  PubMed  Google Scholar 

  209. Preuss UW, Koller G, Zill P, Bondy B, Soyka M. Alcoholism-related phenotypes and genetic variants of the CB1 receptor. Eur Arch Psychiatry Clin Neurosci. 2003;253(6):275–80.

    Article  CAS  PubMed  Google Scholar 

  210. Zuo L, Kranzler HR, Luo X, Covault J, Gelernter J. CNR1 variation modulates risk for drug and alcohol dependence. Biol Psychiatry. 2007;62(6):616–26.

    Article  CAS  PubMed  Google Scholar 

  211. Zuo L, Kranzler HR, Luo X, Yang BZ, Weiss R, Brady K, Poling J, Farrer L, Gelernter J. Interaction between two independent CNR1 variants increases risk for cocaine dependence in European Americans: a replication study in family-based sample and population-based sample. Neuropsychopharmacology. 2009;34(6):1504–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  212. Herman AI, Kranzler HR, Cubells JF, Gelernter J, Covault J. Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(5):499–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  213. Marcos M, Pastor I, de la CC, Barrio-Real L, Laso FJ, Gonzalez-Sarmiento R. Cannabinoid receptor 1 gene is associated with alcohol dependence. Alcohol Clin Exp Res. 2012;36(2):267–71.

    Article  CAS  PubMed  Google Scholar 

  214. Hutchison KE, Haughey H, Niculescu M, Schacht J, Kaiser A, Stitzel J, HortonWJ, Filbey F. The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch Gen Psychiatry. 2008;65(7):841–50.

    Article  PubMed  PubMed Central  Google Scholar 

  215. van den Wildenberg E, Janssen RG, Hutchison KE, van Breukelen GJ, Wiers RW. Polymorphisms of the dopamine D4 receptor gene (DRD4 VNTR) and cannabinoid CB1 receptor gene (CNR1) are not strongly related to cue-reactivity after alcohol exposure. Addict Biol. 2007;12(2):210–20.

    Article  PubMed  CAS  Google Scholar 

  216. Merritt LL, Martin BR, Walters C, Lichtman AH, Damaj MI. The endogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol Exp Ther. 2008;326(2):483–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  217. Schlosburg JE, Carlson BL, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, Lichtman AH. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J. 2009;11(2):342–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  218. Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet. 2004;13(18):2113–9.

    Article  CAS  PubMed  Google Scholar 

  219. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA. 2002;99(12):8394–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  220. Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet. 2006;120(4):581–8.

    Article  CAS  PubMed  Google Scholar 

  221. Iwasaki S, Ishiguro H, Higuchi S, Onaivi ES, Arinami T. Association study between alcoholism and endocannabinoid metabolic enzyme genes encoding fatty acid amide hydrolase and monoglyceride lipase in a Japanese population. Psychiatr Genet. 2007;17(4):215–20.

    Article  PubMed  Google Scholar 

  222. Tyndale RF, Payne JI, Gerber AL, Sipe JC. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(5):660–6.

    Article  CAS  PubMed  Google Scholar 

  223. Hariri AR, Gorka A, Hyde LW, Kimak M, Halder I, Ducci F, Ferrell RE, GoldmanD, Manuck SB. Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function. Biol Psychiatry. 2009;66(1):9–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  224. Glahn DC, Lovallo WR, Fox PT. Reduced amygdala activation in young adults at high risk of alcoholism: studies from the Oklahoma family health patterns project. Biol Psychiatry. 2007;61(11):1306–9.

    Article  PubMed  PubMed Central  Google Scholar 

  225. Buhler KM, Huertas E, Echeverry-Alzate V, Gine E, Moltó E, Montoliu L, López-Moreno JA. Risky alcohol consumption in young people is associated with the fatty acid amide hydrolase gene polymorphism C385A and affective rating of drug pictures. Mol Genet Genomics. 2014;289(3):279–89.

    Article  CAS  PubMed  Google Scholar 

  226. Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol. 2008;28(3):317–24.

    Article  CAS  PubMed  Google Scholar 

  227. George DT, Herion DW, Jones CL, Phillips MJ, Hersh J, Hill D, Heilig M, Ramchandani VA, Geyer C, Spero DE, Singley ED, O'Malley SS, Bishai R, RawlingsRR, Kunos G. Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers. Psychopharmacology (Berl). 2010;208(1):37–44.

    Article  CAS  Google Scholar 

  228. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. The Lancet. 2007;370(9600):1706–13.

    Article  CAS  Google Scholar 

  229. European Medicines Agency. Public statement on Zimulti (Rimonabant) withdrawal of the marketing authorisation in the European Union. European Medicines Agency EMEA/39560/2009. 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500012181.pdf.

  230. Sidhpura N, Parsons LH. Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. Neuropharmacology. 2011;61(7):1070–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  231. McKinley RA, Moorhead HH. Alcoholism. Prog Neurol Psychiatry. 1967;22:459–68.

    Article  CAS  PubMed  Google Scholar 

  232. Hershon HI. Alcohol withdrawal symptoms and drinking behavior. J Stud Alcohol. 1977;38(5):953–71.

    Article  CAS  PubMed  Google Scholar 

  233. De Soto CB, O'Donnell WE, Allred LJ, Lopes CE. Symptomatology in alcoholics at various stages of abstinence. Alcohol Clin Exp Res. 1985;9(6):505–12.

    Article  CAS  PubMed  Google Scholar 

  234. Koob GF. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res. 2003;27(2):232–43.

    Article  CAS  PubMed  Google Scholar 

  235. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, Rodríguez de Fonseca F. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport. 1997;8(2):491–6.

    Article  CAS  PubMed  Google Scholar 

  236. Arevalo C, de Miguel R, Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav. 2001;70(1):123–31.

    Article  CAS  PubMed  Google Scholar 

  237. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl). 2002;159(4):379–87.

    Article  CAS  Google Scholar 

  238. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci. 2002;16(7):1395–8.

    Article  CAS  PubMed  Google Scholar 

  239. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, TarziaG, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 2003;9(1):76–81.

    Article  CAS  PubMed  Google Scholar 

  240. Uriguen L, Perez-Rial S, Ledent C, Palomo T, Manzanares J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology. 2004;46(7):966–73.

    Article  CAS  PubMed  Google Scholar 

  241. Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, Trezza V, La RanaG, Russo R, Calignano A, Gessa GL, Cuomo V, Piomelli D. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology. 2006;31(12):2652–9.

    Article  CAS  PubMed  Google Scholar 

  242. Rutkowska M, Jamontt J, Gliniak H. Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep. 2006;58(2):200–6.

    CAS  PubMed  Google Scholar 

  243. Moreira FA, Kaiser N, Monory K, Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology. 2008;54(1):141–50.

    Article  CAS  PubMed  Google Scholar 

  244. Annis HM, Sklar SM, Moser AE. Gender in relation to relapse crisis situations, coping, and outcome among treated alcoholics. Addict Behav. 1998;23(1):127–31.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Associate, Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA

    Luis A. Natividad

  2. Institute of Neuroscience-Cagliari, National Research Council (CNR), Monserrato, Italy

    Paola Maccioni & Prof. Giancarlo Colombo

  3. Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA

    Loren H. Parsons

Authors
  1. Luis A. Natividad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Maccioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Loren H. Parsons
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Giancarlo Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Loren H. Parsons .

Editor information

Editors and Affiliations

  1. Dept. of Physiology and Pharmacology, Sapienza University, Rome, Italy

    Patrizia Campolongo

  2. Institute of Neuroscience CNR, University of Cagliari, Cagliari, Italy

    Liana Fattore

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Natividad, L., Maccioni, P., Parsons, L., Colombo, G. (2015). Cannabinoid-Alcohol Interactions. In: Campolongo, P., Fattore, L. (eds) Cannabinoid Modulation of Emotion, Memory, and Motivation. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2294-9_14

Download citation

Publish with us

Policies and ethics

Search

Navigation